NSAID trials and the choice of comparators--questions of public health importance.
Psaty
Bruce M
BM
Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, USA.
Weiss
Noel S
NS
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D017327:Clinical Trials, Phase IV as Topic / Q000191:economics / Q000379:methods; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D004008:Diclofenac / Q000009:adverse effects; D017277:Drug Approval / Q000191:economics; D004345:Drug Industry; D000077613:Etoricoxib; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D011725:Pyridines / Q000009:adverse effects; D013450:Sulfones / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration / Q000191:economics
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D011725:Pyridines; D013450:Sulfones; D004008:Diclofenac; D000077613:Etoricoxib